A veterinary sedative synthesized in clandestine labs is showing up in fentanyl at rapidly increasing rates, and it doesn’t respond to naloxone

by Dave Soulia, for FYIVT.com

The Centers for Disease Control and Prevention issued a Health Alert Network advisory on Wednesday warning clinicians, public health agencies, and people who use drugs about a rapidly spreading new adulterant in the illegal fentanyl supply: medetomidine, a veterinary sedative being synthesized in clandestine laboratories and mixed into street opioids at an accelerating pace. Given Vermont’s position squarely in the Northeast — the region with the heaviest detected concentrations — the alert lands with particular urgency here.

Medetomidine, known on the street as “rhino tranq” or “mede,” is approved for sedation in dogs but not for human use. Its dextro-isomer, dexmedetomidine, does have approved procedural sedation applications in hospitals. Forensic testing of illegal drug samples has identified racemic mixtures of medetomidine isomers without the preservatives found in pharmaceutical or veterinary formulations, making diversion of existing products unlikely — suggesting the compound is being synthesized in illicit labs.

The numbers tracking its spread are stark. Reports to the National Forensic Laboratory Information System increased 950% from 247 in 2023 to 2,616 in 2024, followed by a further 215% increase to 8,233 in 2025. Those aren’t rounding errors — that’s exponential contamination of the drug supply. The Northeast accounted for 52% of all detections, with the Midwest at 31%. Vermont sits at the center of the highest-concentration zone.

Wastewater surveillance confirmed the compound’s persistence. From October 2025 through January 2026, medetomidine was detected in treated wastewater every week in at least one of 14 states in a national testing program. Five of five Northeastern sentinel sites detected it in drug samples, and eight sites detected medetomidine in more than 50% of opioid-positive samples during the July–December 2025 monitoring period.

Why Vermont Is Exposed

Vermont’s drug supply is already heavily adulterated. Fentanyl was present in 84% of fatal overdoses in 2022 and 85% in 2023, and xylazine — a previous animal tranquilizer adulterant — appeared in nearly one-third of all fatal overdoses in 2023. The pattern of successive veterinary sedatives entering the fentanyl supply is not new; medetomidine appears to be xylazine’s more potent successor.

Vermont’s opioid overdose deaths fell for the second year in a row in 2024, reaching their lowest annual tally in four years at 183 deaths. That modest progress could be threatened by a compound that evades the primary overdose reversal tool the state has built its harm reduction infrastructure around.

The Naloxone Problem

The core clinical danger medetomidine introduces is a naloxone gap. Naloxone reverses opioid effects — it does not touch medetomidine. Because fentanyl is almost always co-present, naloxone remains the first-line intervention to restore breathing, but sedation from medetomidine may persist even after the opioid component is reversed. A person who received naloxone and still doesn’t wake up is not necessarily beyond help — they may be experiencing medetomidine sedation wearing off on its own timeline.

The overdose presentation includes profound sedation and marked bradycardia — heart rates documented as low as 32 beats per minute — along with hypotension. This differs meaningfully from a standard opioid overdose and can confuse clinical response.

Withdrawal: The Hidden Threat

Arguably more dangerous than the overdose profile is what happens when regular users stop. Stopping medetomidine following regular use can precipitate a severe withdrawal syndrome similar to clonidine withdrawal, with symptoms including tachycardia, severe hypertension, fluctuating alertness, tremor, chest pain, and intractable nausea and vomiting. Symptoms can begin within hours and peak 18 to 36 hours after last use.

The clinical consequences are serious. Complications including non-ST elevation myocardial infarction and posterior reversible encephalopathy syndrome have been associated with severe medetomidine withdrawal. This means someone presenting to a Vermont emergency department with chest pain and uncontrollable vomiting — with no obvious cardiac history — may actually be withdrawing from a compound their fentanyl was cut with, without their knowledge.

From September 2024 through January 2025, 165 patients across three Philadelphia health systems were hospitalized for fentanyl withdrawal complicated by severe autonomic dysfunction. Pittsburgh documented similar cases requiring ICU-level care and dexmedetomidine infusions through March 2025.

For Vermont’s Clinical and First Responder Community

The CDC advises that standard hospital rapid drug screens typically do not include medetomidine. Clinicians should consider it whenever opioid overdose presents with prolonged sedation that doesn’t resolve after adequate naloxone administration, and should consult toxicology or contact poison control at 1-800-222-1222.

Vermont’s existing harm reduction infrastructure — fentanyl test strips, naloxone distribution through syringe service programs, the new Burlington overdose prevention center — was built for a fentanyl-plus-xylazine threat model. Drug test strips are now available for medetomidine detection, though false negatives remain a risk and the strips do not detect some fentanyl analogs. State public health officials and front-line providers will need to assess whether current protocols account for a compound that can leave a naloxone-dosed patient still sedated and heading toward a hypertensive crisis 24 hours later.